DR. LAMISE ZOUKA RAJJOUB MD
Prescription History 1225327240
Ophthalmology - Ophthalmic Plastic and Reconstructive Surgery in Washington, DC

NPI Status: Active since March 30, 2011

Contact Information

2150 PENNSYLVANIA AVE NW
THE GW MEDICAL FACULTY ASSOCIATES
WASHINGTON, DC
ZIP 20037
Phone: (202) 741-3000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. LAMISE ZOUKA RAJJOUB MD, an active Ophthalmic Plastic and Reconstructive Surgery specialist practicing in Washington, DC. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 284 documented patient claims. Among these therapy options, the most frequently utilized medication is Neomycin-Polymyxin-Dexameth, which accounts for 149 claims alone.


Acetaminophen-Codeine

Generic Formulation: Acetaminophen With CodeineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 27
DC State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills35.5
Peer Average Days Supply511
Conservative Utilization

This provider writes prescriptions for this formulation 31.4% less frequently than the standard regional baseline metric for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.35

State Avg Cost Per Claim

$17.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

See also Warning section. This combination medication is used to help relieve mild to moderate pain. It contains an opioid pain reliever (codeine) and a non-opioid pain reliever (acetaminophen). Codeine works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 215
DC State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills24.4
Peer Average Days Supply437
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $412.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.28

State Avg Cost Per Claim

$34.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 344
DC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply351
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $324.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.52

State Avg Cost Per Claim

$26.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Moxifloxacin

Generic Formulation: Moxifloxacin HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 123
DC State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills50.0
Peer Average Days Supply807
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.6% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $373.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.99

State Avg Cost Per Claim

$36.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.

Therapeutic Applications

This medication is a quinolone antibiotic used for eye infections.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 149
30-Day Fills 149.0
Days Supply 1,681
DC State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills34.8
Peer Average Days Supply535
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 338.2% higher than the standard regional baseline profile for DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,976.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.27

State Avg Cost Per Claim

$15.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Tobramycin-Dexamethasone

Generic Formulation: Tobramycin/DexamethasoneSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 44
30-Day Fills 48.1
Days Supply 990
DC State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills42.6
Peer Average Days Supply878
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,041.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.14

State Avg Cost Per Claim

$81.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.

Therapeutic Applications

This medication is used to treat or prevent eye infections. This medication contains two drugs. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. Dexamethasone belongs to a class of drugs called corticosteroids. It works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Tramadol Hcl

Generic Formulation: Tramadol HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 19
DC State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply515
Conservative Utilization

This provider writes prescriptions for this formulation 48.3% less frequently than the standard regional baseline metric for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$0.94

State Avg Cost Per Claim

$8.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A narcotic analgesic proposed for severe pain. It may be habituating.

Therapeutic Applications

See also Warning section. This medication is used to help relieve moderate to moderately severe pain. Tramadol belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. LAMISE ZOUKA RAJJOUB MD provides transparency into local medical care patterns within Washington, DC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmic Plastic and Reconstructive Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.